Matches 1 - 50 out of 182 1 2 3 4 >
Match Document Document Title
7390888 Dendritic cell potentiation  
A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are...
7390490 Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine  
There are provided uses of an antibody directed to CX3CR1 and fractalkine. Killer lymphocytes can be readily identified, eliminated and separated by using an anti-CX3CR1 antibody. Further, there...
7381802 Human antibodies that specifically recognize the toxin Cn2 from Centruroides noxius scorpion venom  
The present invention is directed to recombinant human antibodies specific for Cn2 toxin from C. noxius scorpion venom. The antibodies are able to recognize the toxin and preferably neutralize it...
7381407 Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen  
The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods...
7378094 Therapeutic uses of complement receptor 2  
The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune...
7361345 Anti-CD40 antibodies capable of blocking B-cell activation  
Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen...
7361336 Methods of cancer therapy targeted against a cancer stem line  
Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous...
7354586 Methods of treating arthritis and diabetic retinopathy with αvβ3-specific antibodies  
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
7329406 Methods of treating psoriasis with αvβ3-specific antibodies  
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
7323171 Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction  
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
7291333 Blockade of protein C activation reduces microvascular surgical blood loss  
A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of...
7291330 MD-1 inhibitors as immune suppressants  
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an agent that inhibits MD-1 with or without an OX-2 protein or a...
7279158 Methods for the treatment of inflammatory joint disease  
The use of compounds that block complement component C5 or its active fragments C5 a and/or C5 b (such compounds collectively referred to as “C5 blockers”) to treat established joint...
7276237 Human Mob-5 (IL-24) receptors and uses thereof  
The present invention provides the receptors for Mob-5 (IL-24). One of the Mob-5 receptors comprises IL-22R1 and IL-20R2. Another Mob-5 receptor comprises IL-20R1 and IL-22R2. The invention also...
7267819 Composition comprising and method of using angiopoietin-like protein 3 Angptl3  
The present invention is directed to methods and means for making and using Angptl3 polypeptides. The invention specifically concerns the use of Angptl3 polypeptides in inducing liver regeneration...
7259247 Anti-human T-cell costimulating polypeptide monoclonal antibodies  
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the...
7223842 Detection of proteins whose absence is associated with a neoplasm  
This invention relates to nucleic acid, or fragments thereof, encoding the retinoblastoma polypeptide, the retinoblastoma polypeptide itself, methods of detecting a defective retinoblastoma gene in...
7208150 Analgesic from snake venom  
A substantially non-toxic fraction isolated from snake venom is disclosed, which fraction has an analgesic effect. The fraction has the characteristics of a fraction from snake venom purified on a...
7138502 Antibodies to the propeptide of Candida albicans and methods of use  
Antibodies and agents which can bind to the propeptide of the Int1p protein of yeast microorganisms such as Candida albicans are provided which can be useful in methods for treating or preventing...
7135182 Inhibition of transglutaminase-mediated microbial interaction with a mammalian host  
The infection of a mammalian host by a microorganism can be prevented or treated through the administration of substrates for transglutaminases or antibodies against such substrates that inhibit...
7132099 Methods of modulating T lymphocyte costimulation with an antibody to an 8F4 polypeptide  
A polypeptide (8F4 molecule) with a T-cell costimulating biological activity is disclosed, as well as monoclonal antibodies against said 8F4 molecule and hybridoma cells which produce the...
7125551 Methods for treatment of asthmatic disorders using a monoclonal antibody to 8F4 polypeptide  
The present invention relates to methods and compositions for the prevention and treatment and prevention of immune system disorders, including cancer, AIDS, asthmatic disorders, autoimmune...
7074403 Immunotherapy of autoimmune disorders using antibodies which target B-cells  
Antibodies that bind with a B-cell antigen provide an effective means to treat autoimmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal...
7067132 Antagonists of interleukin-15  
Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15Rα-subunit and that are...
7060271 Inhibitory immunoglobulin polypeptides to human PDGF beta receptor  
The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin...
7052694 Dendritic cell potentiation  
A molecule capable of potentiating immune responses is described, as well as methods for using the molecule to enhance immune responses and enhance dendritic cell function. Also described are...
7041292 Treating prostate cancer with anti-ErbB2 antibodies  
The present application discloses treatment of prostate cancer with anti-ErbB2 antibodies.
7001597 Methods for altering fertility  
The present invention relates to methods for enhancing fertility by reducing the activities and/or levels of circulating glycoprotein hormones having lutropin (LH) activity. The molecules of the...
6969516 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration  
A method is described comprising the combined administration of a novel composition comprising serum complement proteins with complement-fixing antibodies to induce transient disruption of myelin...
6960560 Iron chelator delivery system  
An iron chelator delivery system is disclosed. The system comprises iron chelator and a lipid carrier, e.g., a liposome. Methods for preparing and administering the iron chelator delivery system...
6949245 Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies  
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
6936262 LktA deletion mutant of P. haemolytica  
Mutants of P. haemolytica provide excellent safety and efficacy when used as vaccines in ruminants, for example cattle, sheep, and goats, subject to pneumonic pasteurellosis. They can be...
6927023 Method of identifying modulators of HIV-1 Vpu and Gag interaction with U binding protein (Ubp)  
A preparation of U binding protein (Ubp) and a gene sequence encoding Ubp and an anti-Ubp antibody are disclosed. An assay to identify modulators of Ubp/Vpu interaction and Gag/Ubp interaction is...
6921533 Method of using monoclonal antibodies against leukocyte adhesion receptor β-chain  
Monoclonal antibodies and method for ameliorating an immune response disorder. The monoclonal antibodies are specific for an epitope present on the leukocyte adhesion receptor β-chain.
6899879 Method for treating an IgE-mediated disease in a patient using anti-CD40 monoclonal antibodies  
Methods for preventing or treating an IgE-mediated allergic disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40...
6887473 Inhibition of angiogenesis in disease states with an anti-αvβ3 monoclonal antibody  
The present invention describes methods for inhibition angiogenesis in tissues using vitronectin α v β 3 antagonists, and particularly for inhibiting angiogenesis in inflamed tissues and in...
6818215 Antibodies to senescent cell-derived inhibiters of DNA synthesis  
Polyclonal and monoclonal antibodies that specifically bind senescent cell derived inhibitor protein (SDI-1), cell lines that produce such monoclonal antibodies, and the use of such antibodies are...
6808710 Downmodulating an immune response with multivalent antibodies to PD-1  
The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents...
6803039 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM  
Immunization of human antibody-producing transgenic mice, which have been created using genetic engineering techniques, with AILIM molecule as an antigen resulted in various human monoclonal...
6774219 Candida albicans gene, integrin-like protein, antibodies, and methods of use  
An isolated and purified DNA molecule encoding Candida albicans protein with integrin-like motifs, the protein itself, antibodies thereto, and methods of use, are provided.
6767541 HER-2/neu overexpression abrogates growth inhibitory pathways  
The present invention provides methods for obtaining genetic profiles of cancer cells in order to assess the status of a cancer in an individual. In addition, the present invention provides methods...
6764681 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction  
Methods of using inhibitors of the CD2/LFA-3 interaction in treating skin conditions characterized by increased T cell activation and abnormal antigen presentation in the dermis and epidermis in...
6759519 Antibodies to human G-protein chemokine receptor HDGNR10 (CCR5receptor)  
Antibodies against human G-protein chemokine receptor polypeptides, the polypeptides themselves, DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant...
6737058 Methods for inhibiting endothelial cell and fibrinogen mediated inflammation using fibrinogen specific antibodies  
The present invention contemplates therapeutic compositions containing a fibrinogen homolog capable of binding to endothelial cells in an RGD-independent manner that inhibits fibrinogen binding to...
6696480 Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization  
A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell...
6693175 Method for diagnosing bone dysbolism  
A method of diagnosing metabolic bone diseases, especially osteoporosis and arthrosis characterized by determining the concentration of osteoclastgenesis inhibitory factor (OCIF) in humor. ...
6692743 Apoptosis of naive human NK cells by crosslinking of their Fc&ggr RIIIa molecules with a rat IgG2b (LO-CD2a/BTI-322) or its IgG1 humanized monoclonal antibody  
Although the mechanism of induction of apoptosis through antibody dependent cellular cytotoxicity (ADCC) mediated by NK cells is well understood, little is known about the fate of the reactive NK...
6689360 Human B-cell translocation genes-2 and 3 antibodies  
The present invention relates to antiproliferative genes. More specifically, isolated nucleic acid molecules are provided encoding the human B-cell translocation genes 2 and 3 (BTG-2 and BTG-3)....
6667036 Methods of treatment using antibodies to P-selectin glycoprotein ligand  
P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [ 3...
6663863 Method of inhibiting stenosis and restenosis  
The invention relates to a method of inhibiting stenosis or restenosis in a subject. In one embodiment, an agent which inhibits recruitment and/or adhesion of neutrophils and mononuclear cells to a...
Matches 1 - 50 out of 182 1 2 3 4 >